Delcath stock.

Delcath will host a conference call today, on March 27, 2023, at 4:30 PM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2022 and provide a business update ...united states. securities and exchange commission. washington, d.c. 20549 . form 10-qAug 15, 2023 · Crazy to sell under $8.5-9 "Delcath Systems price target raised to $18 from $14 at Canaccord Canaccord raised the firm's price target on Delcath Systems to $18 from $14 and keeps a Buy rating on ... Aug. 14, 2023 at 5:32 p.m. ET on Benzinga.com. DCTH | Complete Delcath Systems Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full …

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that it plans to report the Company's ...In the last 3 months, 5 analysts have offered 12-month price targets for Delcath Systems. The company has an average price target of $17.2 with a high of $20.00 and a low of $13.00.

52 Week Low Date 10/13/22. Market Cap 63.773M. Shares Out 10.62M. 10 Day Average Volume 0.02M. Dividend -. Dividend Yield -. Beta 0.85. YTD % Change 66.8.

DELCATH SYSTEMS, INC. (Name of Registrant as Specified In Its Charter) ROBERT B. LADD ...Received stockholders approval for the potential issuance in excess of 19.99% of Delcath's outstanding common stock upon the conversion of the preferred stock issued pursuant to a private placement that closed on March 29, 2023 and generated $25 million on closing with up to an additional $35 million expected upon the exercise of warrants into ...Oct. 24, 2022 9:34 AM ET Delcath Systems, Inc. (DCTH) SA Transcripts. 142.46K Follower s. The following slide deck was published by Delcath Systems, Inc. in conjunction with this event. View as ...Get the latest Delcath Systems Inc (DCTH) stock quote, charts, news, and other financial information to help you make more informed trading and investment decisions. See the company's financial performance, balance sheet, cash flow, and market outlook for the second quarter of 2023. Delcath Systems, Inc. 27 Mar, 2023, 08:15 ET. Led by Vivo Capital with participation from Logos Capital, BVF Partners LP, Stonepine Capital Management, LLC, Serrado Capital LLC and supported by ...

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of an article ...

DCTH: Delcath Systems Inc Stock Price Quote - NASDAQ CM - Bloomberg Subscribe S&P 500 4,567.80 +0.38% Nasdaq 14,226.22 –0.23% Crude Oil 75.62 …

Insider Buying: Delcath Systems, Inc. (NASDAQ:DCTH) COO Purchases $49,897.20 in Stock Ticker Report • about 1 month ago Delcath Systems, Inc. (NASDAQ:DCTH Get Free Report) COO John Purpura acquired 14,505 shares of the stock in a transaction dated Friday, October 13th.... DCTH shares relative to the market in the next few months. In addition, Delcath Systems, Inc. has a VGM Score of D (this is a weighted average of the ...May 12, 2023 · Delcath Systems, Inc. (Nasdaq: DCTH) (Delcath or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business ... Source: Kantar Media. View the latest Delcath Systems Inc. (DCTH) stock price, news, historical charts, analyst ratings and financial information from WSJ.Is the chair of Delcath’s audit committee independent? Delcath Systems, Inc. (NASDAQ-DCTH) is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. A full list of Delcath’s investor FAQs including investor information, financial and shareholder information and corporate governance information.Nov 28, 2023 · Delcath Systems (DCTH) Company Description: Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. Delcath Systems, Inc. Common Stock (DCTH) Stock Price, Quote, News & History | Nasdaq. amount that a seller is currently willing to sell. The numbers next to the bid/ask are the “ when trading ...

Complete Delcath Systems Inc. stock information by Barron's. View real-time DCTH stock price and news, along with industry-best analysis.Earnings for Delcath Systems are expected to grow in the coming year, from ($2.43) to ($1.45) per share. Delcath Systems has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 25th, 2024 based off prior year's report dates. Read More.Insiders trading at Delcath Systems. Over the last 4 years, insiders at Delcath Systems have traded over $0 worth of Delcath Systems stock and bought 1,064,320 units worth $8,436,426 . The most active insiders traders include Marco Taglietti, Gerard J Michel, and Advisors, Inc. Rosalind.On average, Delcath Systems executives …Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. We are a specialty pharmaceutical and medical device company developing our proprietary product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). Is the chair of Delcath’s audit committee independent? Delcath Systems, Inc. (NASDAQ-DCTH) is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. A full list of Delcath’s investor FAQs including investor information, financial and shareholder information and corporate governance information.

united states. securities and exchange commission. schedule 14a (rule 14a-101) information required in proxy statement. schedule 14a information. proxy statement pursuant to section 14(a) of the securities exchange act of 1934

NEW YORK, Sept. 22, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary...Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded in August 1988 and is headquartered in New York, NY. DCTH - Delcath Systems Inc - Stock screener for investors and traders, financial visualizations.15.2%. 10% least volatile stocks in US Market. 2.9%. Stable Share Price: DCTH is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week. Volatility Over Time: DCTH's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.Exercise: Stock options may be exercised at any time, once vested, and have true value when the exercise price is more than the grant price of the award. More information on how to exercise stock options are described in greater detail in Delcath’s Amended 2009 Stock Incentive Plan and applicable Awards Agreements. •-----begin privacy-enhanced message----- proc-type: 2001,mic-clear originator-name: [email protected] originator-key-asymmetric ...Nov 22, 2023 · Delcath Systems to raise $5M in stock and warrants offering SA News Mon, Jul. 18, 2022 Delcath Systems GAAP EPS of -$1.00 misses by $0.12, revenue of $0.38M beats by $0.07M DCTH. --Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results ...PR Newswire (US) NEW YORK, Oct. 10, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the ...DELCATH SYSTEMS, INC. (Name of Registrant as Specified In Its Charter) ROBERT B. LADD ...May 17, 2022 · Company Overview: Delcath Systems Inc. owns a medical device approved in Europe and a drug-device candidate pursuing approval in the U.S. The company is based in the Big Apple. Currently the ...

Discover historical prices for DCTH stock on Yahoo Finance. View daily, weekly or monthly format back to when Delcath Systems, Inc. stock was issued.

52 Week Low Date 10/13/22. Market Cap 63.773M. Shares Out 10.62M. 10 Day Average Volume 0.02M. Dividend -. Dividend Yield -. Beta 0.85. YTD % Change 66.8.

DCTH | August 9, 2023. NEW YORK, Aug. 9, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the second quarter ended June 30, 2023.4 brokers have issued twelve-month target prices for Delcath Systems' shares. Their DCTH share price targets range from $13.00 to $21.00. On average, they predict the company's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 542.9% from the stock's current price. View analysts price targets …Almost a decade after Delcath suffered an FDA rejection for its drug/device combo, ... Delcath's stock price nearly doubled after the FDA approval and was trading at around $6.00 on Tuesday morning.Dividends. A high-level overview of Delcath Systems, Inc. (DCTH) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.In the last 3 months, 5 analysts have offered 12-month price targets for Delcath Systems. The company has an average price target of $17.2 with a high of $20.00 and a low of $13.00. Below is a ...View Our Latest Stock Analysis on DCTH. Delcath Systems Price Performance. NASDAQ DCTH opened at $2.45 on Thursday. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.30 and a quick ratio of 1.53. The stock’s fifty day moving average price is $3.62 and its 200 day moving average price is $4.93.Delcath Systems, Inc. is an interventional oncology company. The Company is focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO Kit (melphalan hydrochloride for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to ...When we look at Delcath Systems Inc’s average trading volume, we note the 10-day average is 0.54 million shares, with the 3-month average coming to 413.15K. Analysts gave the Delcath Systems Inc (DCTH) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.00.Aug 16, 2023 · In the last 3 months, 5 analysts have offered 12-month price targets for Delcath Systems. The company has an average price target of $17.2 with a high of $20.00 and a low of $13.00. Below is a ... DCTH | October 10, 2023. NEW YORK, Oct. 10, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that it will be participating in the Lytham Partners Fall 2023 Investor Conference taking place virtually on Tuesday, …Mar 27, 2023 · Delcath will host a conference call today, on March 27, 2023, at 4:30 PM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2022 and provide a business update ...

Data Provided by Thomson Reuters. Delcath Systems, Inc. (NASDAQ-DCTH) is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. See all of Delcaths investors and understand how they are helping revolutionize how cancer is treated.Feb 7, 2020 · Since the stock is closer to the resistance from accumulated volume at $12.00 (17.07%) than the support at $8.30 (19.02%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level. Is Delcath Systems stock A Buy? According to 4 analysts, the average rating for DCTH stock is "Strong Buy." The 12-month stock price forecast is $18.0, which is an increase of 542.86% from the latest price.Company Overview: Delcath Systems Inc. owns a medical device approved in Europe and a drug-device candidate pursuing approval in the U.S. The company is based in the Big Apple. Currently the ...Instagram:https://instagram. vanguard open sep irathinkorswim charles schwabadidas company stockwebull paper trading app -----begin privacy-enhanced message----- proc-type: 2001,mic-clear originator-name: [email protected] originator-key-asymmetric ...Earnings for Delcath Systems are expected to grow in the coming year, from ($2.43) to ($1.45) per share. Delcath Systems has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 25th, 2024 based off prior year's report dates. Read More. renters insurance like lemonadehome inventory application Delcath Systems (NASDAQ: DCTH) stock is rocketing higher on Tuesday after getting an update from the U.S. Food and Drug Administration (FDA). This has the FDA approving HEPZATO KIT. This is ...Delcath Systems (NASDAQ: DCTH) stock is rocketing higher on Tuesday after getting an update from the U.S. Food and Drug Administration (FDA). This has the FDA approving HEPZATO KIT. top gold brokers -----begin privacy-enhanced message----- proc-type: 2001,mic-clear originator-name: [email protected] originator-key-asymmetric ...Discover historical prices for DCTH stock on Yahoo Finance. View daily, weekly or monthly format back to when Delcath Systems, Inc. stock was issued.